Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, .
Skye Bioscience, Inc.March 8, 2021 GMT
San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today the appointment of scientific innovators and cannabinoid experts, Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to its scientific advisory board.
“We are honored to welcome two of the world’s most influential thought leaders in cannabinoid science, Drs. Appendino and Muñoz, to our scientific advisory board as we continue to advance our research and deepen our understanding of cannabinoid-based medicines,” said Punit Dhillon, Chief Exec